Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Fineline Cube Jun 22, 2026
Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Fineline Cube Jun 22, 2026
Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Fineline Cube Jun 22, 2026
Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Fineline Cube Jun 22, 2026
Company Drug

Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC

Fineline Cube Jun 22, 2026
Company Deals

MaxHealth Biotechnology Completes Series B+ Financing Round

Fineline Cube Dec 7, 2022

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...

Company Drug

MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe

Fineline Cube Dec 7, 2022

Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...

Company Deals

F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again

Fineline Cube Dec 7, 2022

UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...

Company Deals

ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy

Fineline Cube Dec 6, 2022

Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...

Company Drug

Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 6, 2022

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...

Company Deals

Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform

Fineline Cube Dec 6, 2022

Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...

Hospital

Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting

Fineline Cube Dec 6, 2022

The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...

Deals Hospital

United Family Healthcare Partners with HSS for Orthopedic Collaboration

Fineline Cube Dec 6, 2022

United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...

Company Medical Device

MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification

Fineline Cube Dec 6, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...

Company Drug

Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers

Fineline Cube Dec 6, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...

Company Deals

Akeso Biopharma Plans IPO on Shanghai’s STAR Market

Fineline Cube Dec 6, 2022

China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...

Company

Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups

Fineline Cube Dec 6, 2022

Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...

Company Deals

Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets

Fineline Cube Dec 6, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...

Company Drug

WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 5, 2022

Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...

Company Drug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

Fineline Cube Dec 5, 2022

China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...

Company Deals Digital

China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma

Fineline Cube Dec 5, 2022

China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...

Company Drug

Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study

Fineline Cube Dec 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...

Company Drug

Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...

Company Medical Device

Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA

Fineline Cube Dec 5, 2022

Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...

Company Drug

Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China

Fineline Cube Dec 5, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...

Posts pagination

1 … 611 612 613 … 686

Recent updates

  • Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
  • CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
  • Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
  • Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio
  • Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.